8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 7, 2005


                            INGEN TECHNOLOGIES, INC.
             (Exact name of registrant as specified in its charter)


             Georgia                    need #                88-0429044
             -------                 -----------              ----------
 (State or other jurisdiction of     (Commission           (I.R.S. Employer
 incorporation or organization)      File Number)        Identification Number)

 35193 Avenue "A", Suite-C, Yucaipa, California                 92399
 ----------------------------------------------                 -----
    (Address of principal executive offices)                  (Zip Code)

                                 (800) 259-9622
                                 --------------
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     [ ]  Written communications pursuant to Rule 425 under the Securities Act
          (17 CFR 230.425)

     [ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
          CFR 240.14a-12)

     [ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
          Exchange Act (17 CFR 240.14d-2(b))

     [ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
          Exchange Act (17 CFR 240.13e-4(c))




2.02 Results of Operations and Financial Condition.

         On March 7, 2006, Ingen Technologies, Inc. reported sales of $846,269
for the period of June 1, 2005 to February 28, 2006 (the first 3 quarters of our
fiscal year). The company also stated that we have $225,000 accrued sales
deferred into the last quarter of this fiscal year (ending on May 31, 2006).

         The press release, which contained other matters as well, is included
herewith as an Exhibit.



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated:  March 14, 2006              Ingen Technologies, Inc.


                                    By: /s/ Scott R. Sand
                                        -------------------------------------
                                        Scott R. Sand,
                                        Chief Executive Officer and Chairman



TABLE OF EXHIBITS
(All Exhibits have been properly signed by the parties.
Original agreements are filed in our offices)


      EXHIBIT NO.             DESCRIPTION

         99.1         Press Release of March 7, 2006.

EX-99.1

Exhibit 99.1

CALIMESA, CA - MARCH 7, 2006 -- Ingen Technologies, Inc. (OTC: IGTG), a medical
device manufacturer of OxyAlertTM, OxyViewTM, and Secure BalanceTM, announced
today that its third quarter sales compared to last year have increased
substantially.

The total sales from June 1, 2005 through February 28, 2006 are $846,269, and in
addition there are $225,000 in orders during this period with scheduled
deliveries for March and April. Last year, total sales from June 1, 2004 through
February 28, 2005 were $501,758. This year has an increase of more than $300,000
in cash sales with an additional $225,000 accrued sales deferred for next
quarter.

The company has engaged the Newport Beach-California law offices of Richard O.
Weed to prepare the documents necessary for OTC-Bulletin Board status. Mr. Weed
has engaged a Market Maker to qualify IGTG with the NASD. "With the last 2 years
of IGTG audited returns filed, inclusive of all of the 10-KSB(s) and 10-QSB(s),
the NASD requires that the company have the past two years filed, and are
current with their most recent quarters in order to qualify for the OTC-BB",
Said Thomas J. Neavitt, CFO. The law office of Peter J. Wilke has recently
prepared and filed the 10-QSB(s) for 2003 in order to complete the past 2 years
(2004 and 2005) respectively.

The company has engaged Anita Beck, President of Global Regulatory Services
Associates in San Juan Capistrano-California, to provide the company with
information pertaining to the requirements for registration of the OxyView(TM)
product. Anita Beck will prepare the appropriate submission to FDA, if a
submission should be required. The company expects to have the FDA requirements
complete and satisfactory in the very near future in order to market
OxyView(TM). "This affords the company to tap into the $15M per year revenue
stream suggested by the Chartered Financial Analyst Report." Said Chris Wirth,
Director.

"Ingen is moving fast at this time. Anita Beck has submitted the OxyView(TM)
material with the FDA and is in close communication, along with the OTC-BB
finally being submitted for approval and under control by attorney Richard Weed,
and with the SEC filings current from the quarter ending August 30, 2003 and
under control with attorney Peter Wilke; the company will experience another
benchmark in our attempt to continue forward positive growth in revenues and
products." Said Scott Sand, Chairman and CEO.


ABOUT INGEN TECHNOLOGIES, INC.

Ingen Technologies, Inc. is a public company trading under NASDAQ OTC:IGTG,
which has been in business since 1999. IGTG is a medical device manufacturer and
a growth-oriented company that owns US patent(s), trademarks, and proprietary
medical products.

The Company's flagship product is OxyAlert(TM), a second-generation design of
the Company's BAFI(TM) product line. Both of these products have been issued two
US Patents: Patent No. 6,137,417 issued on October 24, 2000 and Patent No.
6,326,896 issued on December 4, 2001. Both of these products are low-oxygen
safety warning devices used on remote oxygen cylinders for patients, commercial
aircraft, military transport, and fire and safety equipment. OxyAlert(TM)
technology encompasses the use of digital sensing and RF frequency transfer so
that care givers can access a hand-held remote to monitor the actual oxygen
level of any oxygen cylinder at a reasonable distance.

The newest product, OxyView(TM), has a patent pending, and is a pneumatic gauge
that provides visual safety warning of oxygen flow for patients in the hospital,
surgical room, outpatient therapy, nursing homes and emergency response
facilities. This product enhances the safety, assurance and accuracy of patients
being administered oxygen from any source. OxyView(TM) is a lightweight
pneumatic gauge that is attached to the oxygen tubing just below the neck. It
informs the nursing staff of the oxygen flow rate near the patient. It could
quickly inform the physician or technician of any leak or inaccuracy between the
delivery source and the patient.



The Secure Balance(TM) product is a private-label product that includes a
vestibular function testing system and balance therapy system. The vestibular
function testing system is manufactured by Interacoustics LTD. in Denmark and is
referred to as the VNG. The balance therapy system is manufactured by
SportKAT(R), Inc. in San Diego, California. The Secure Balance(TM) program
provides equipment, education and training about balance and fall prevention to
physicians and clinicians worldwide.

The Pure Produce(TM) product is a continuing research & development program
currently under design. This program uses hydroponics technology to grow various
plants without the use of soil, fertilizer and water consumption. The Company
anticipates entering the nutriceutical and pharmaceutical markets over the next
two years.

"Our team of professionals has developed our medical products for the
ever-increasing elderly population. Our products are superior to any of our
competition and they allow for effective medical product availability to
seniors, and at the same time the increasing senior population allows for a
steady growth in sales and profits," said Scott Sand, CEO & Chairman of Ingen
Technologies.

For more information, visit  www.ingen-tech.com
                             ------------------

Investor Relations Contact:  Scott R. Sand, C.E.O & Chairman
Ingen Technologies, Inc. - Administrative Office
35193 Avenue "A", Suite-C
Yucaipa, California 92399
Phone: (800) 259-9622 or (909) 790-7180
Fax: (800) 777-1186 or (909) 795-6340
Email: Info@ingen-tech.com
A Member of the Better Business Bureau
A Member of the Chamber of Commerce
     A Licensed Business in the City of Yucaipa

Safe Harbor for Forward-Looking Statements: This news release includes
forward-looking statements that are made pursuant to "Safe Harbor" provisions of
the Private Securities Litigation Reform Act of 1995. While these statements are
made to convey to the public the company's progress, business opportunities and
growth prospects, readers are cautioned that such forward-looking statements
represent management's opinion. Whereas management believes such representations
to be true and accurate based on information and data available to the company
at this time, actual results may differ materially from those described. The
company's operations and business prospects are always subject to risk and
uncertainties. Important factors that may cause actual results to differ will be
set forth in the company's periodic filings with the U.S. Securities and
Exchange Commission.